Melinta

Melinta

Providing innovative therapies for acute and life-threatening illnesses.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor investor investor investor investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
*

$300m

Acquisition
Total Funding000k
Notes (0)
More about Melinta
Made with AI
Edit

Melinta Therapeutics is a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat serious bacterial infections. Operating in the healthcare and pharmaceutical markets, Melinta serves hospitals, healthcare providers, and patients who are in need of effective treatments for resistant bacterial infections. The company's business model revolves around research and development (R&D) of new antibiotics, followed by the commercialization of these drugs through sales and partnerships. Revenue is generated primarily through the sale of its antibiotic products and licensing agreements. Melinta's mission is to address the continually evolving threat of bacterial infections by providing innovative solutions that meet the needs of patients and healthcare providers. The company emphasizes collaboration, inclusivity, and agility in its operations to achieve ambitious goals and make a significant impact in the field of infectious diseases.

Keywords: antibiotics, bacterial infections, biopharmaceutical, healthcare, pharmaceutical, hospitals, R&D, commercialization, licensing, infectious diseases.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo